Fire1

Executive Summary

Fire1 is a privately-held medical device company headquartered in Dublin, Ireland, focused on transforming heart failure (HF) management through its innovative NORM system. The platform features an implantable sensor placed in the inferior vena cava (IVC) that provides direct, daily measurements of central venous pressure (CVP) and fluid volume status. This enables clinicians to remotely monitor patients and intervene early before decompensation occurs, potentially reducing hospitalizations and improving quality of life. Unlike external monitoring solutions, Fire1's implantable approach offers continuous, objective data that removes patient compliance barriers. With heart failure affecting over 64 million people globally and hospitalization costs exceeding $30 billion annually in the U.S. alone, the NORM system addresses a critical unmet need for scalable, data-driven remote management. Fire1 has completed initial clinical feasibility studies and is advancing toward pivotal trials to support FDA and CE mark submissions. The company's technology has been well-received in early feasibility studies, demonstrating safety and accurate fluid volume assessment. As an emerging player in the cardiovascular digital health space, Fire1 faces competition from other implantable hemodynamic monitors and wearable-based solutions, but its direct fluid volume measurement offers a differentiated value proposition. The company is likely seeking additional funding or partnerships to accelerate commercialization. If successful, Fire1 could capture a significant share of the rapidly growing remote HF monitoring market, which is projected to exceed $20 billion by 2030.

Upcoming Catalysts (preview)

• Q4 2026Initiation of Pivotal Clinical Trial70% success
• Q3 2026FDA Breakthrough Device Designation or IDE Approval80% success
• TBDStrategic Partnership for U.S. Commercialization50% success